Breast cancer (BC) has been ranked the most common malignant tumor throughout the
world and is also a leading cause of cancer-related deaths among women. SRC family …

Profound progress has been made in cancer treatment in the past three decades. However,
drug resistance remains prevalent and a critical challenge. Drug resistance can be attributed …

Background Resistance to chemotherapy, combined with heterogeneity among resistant
tumors, represents a significant challenge in the clinical management of triple negative …

Triple negative breast cancer (TNBC) is a heterogeneous group of tumors which lack
estrogen receptor, progesterone receptor, and HER2 expression. Targeted therapies have …

Precision oncology relies on detailed molecular analysis of how diverse tumours respond to
various therapies, with the aim to optimize treatment outcomes for individual patients. Patient …

Introduction Given the poor prognosis of patients with TNBC, it is urgent to identify new
biomarkers and therapeutic targets to enable personalized treatment strategies and improve …

Triple-negative breast cancer (TNBC) is the most aggressive subtype of breast cancer with
few treatment options. A promising TNBC treatment approach is targeting the oncogenic …

Tyrosine kinases play a crucial role in cell proliferation and survival and are extensively
investigated as targets for cancer treatment. However, the efficacy of most tyrosine kinase …

Breast cancers (BRCA) exhibit substantial transcriptional heterogeneity, posing a significant
clinical challenge. The global transcriptional changes in a disease context, however, are …

Breast cancer is a heterogeneous disease with multiple subtypes and presents significant
challenges in treatment due to the development of therapeutic drug resistance. This …